KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Cash (2016 - 2025)

Historic Change in Cash for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $12.2 million.

  • Inovio Pharmaceuticals' Change in Cash rose 19615.2% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 41614.88%. This contributed to the annual value of $51.5 million for FY2024, which is 26085.21% up from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Change in Cash of $12.2 million as of Q3 2025, which was up 19615.2% from -$15.6 million recorded in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Change in Cash peaked at $44.1 million during Q4 2024, and registered a low of -$167.1 million during Q1 2021.
  • In the last 5 years, Inovio Pharmaceuticals' Change in Cash had a median value of -$12.1 million in 2022 and averaged -$11.3 million.
  • In the last 5 years, Inovio Pharmaceuticals' Change in Cash skyrocketed by 108193.97% in 2024 and then plummeted by 58947.29% in 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Change in Cash (Quarter) stood at $3.2 million in 2021, then soared by 660.08% to $24.3 million in 2022, then plummeted by 118.46% to -$4.5 million in 2023, then skyrocketed by 1081.94% to $44.1 million in 2024, then tumbled by 72.32% to $12.2 million in 2025.
  • Its Change in Cash was $12.2 million in Q3 2025, compared to -$15.6 million in Q2 2025 and -$25.9 million in Q1 2025.